ライフサイエンスコーパス: intestinal fatty acid-binding protein

1 ll differentiation, alkaline phosphatase and intestinal fatty acid binding protein.

2 lline concentration and its correlation with intestinal fatty acid-binding protein.

3 failed to express the differentiation marker intestinal fatty acid-binding protein.

4 e fatty acid binding site of recombinant rat intestinal fatty acid binding protein (1-FABP).

5 e of conformational fluctuations of unfolded intestinal fatty acid binding protein (131 aa, 15 kDa) b

6 rved mucosal abnormalities, plasma levels of intestinal fatty acid binding protein, a marker of enter

7 s a set of molecular dynamics simulations of intestinal fatty acid binding protein addressing the pro

8 port new measurements, using the acrylodated intestinal fatty acid binding protein (ADIFAB) method, o

9 was monitored by using the acrylodan-labeled intestinal fatty acid binding protein and HPLC.

10 ma gut epithelial barrier integrity markers (intestinal fatty acid binding protein and zonulin-1 leve

11 Plasma intestinal fatty acid-binding protein and citrulline con

12 was no correlation between plasma levels of intestinal fatty acid-binding protein and citrulline.

13 ifferentiation defects such as expression of intestinal fatty acid-binding protein and pancreatic try

14 The link between intestinal fatty acid-binding protein and plasma citrull

15 lyzed plasma levels of soluble CD14 (sCD14), intestinal fatty acid binding protein, and interleukin-6

16 ling constants in ubiquitin (alphabeta-fold) intestinal fatty acid binding protein (beta-barrel) and

17 c epithelial markers, the intestinal markers intestinal fatty acid binding protein, CDX1 and CDX2 wer

18 plasma citrulline</=12.2 mumol/L, and plasma intestinal fatty acid-binding protein concentration>/=35

19 Intestinal fatty acid-binding protein elevation at admis

20 tiated as gauged by significant reduction of intestinal fatty acid-binding protein expression.

21 cytes under the control of elements from the intestinal fatty acid binding protein gene (Fabpi).

22 ansgenic mice were studied that contained an intestinal fatty acid binding protein gene promoter (Fab

23 The equilibrium unfolding behavior of the intestinal fatty acid-binding protein has been investiga

24 nts were made on PA bound to recombinant rat intestinal fatty acid binding protein (I-FABP) at pH 5.5

25 The human intestinal fatty acid binding protein (I-FABP) belongs t

26 The intestinal fatty acid binding protein (I-FABP) belongs t

27 6, and a gut microbial translocation marker (intestinal fatty acid binding protein (I-FABP)) were mea

28 The enterocyte-specific protein, intestinal fatty acid binding protein (I-FABP), is detec

29 We measured plasma intestinal fatty acid binding protein (I-FABP), soluble

30 Analogous to that in the intestinal fatty acid binding protein (I-FABP), we hypot

31 ing protein (LBP), soluble CD14 (sCD14), and intestinal fatty acid binding protein (I-FABP).

32 Intestinal fatty acid-binding protein (I-FABP) binds a s

33 Intestinal fatty acid-binding protein (I-FABP) binds FFA

34 three-dimensional solution structure of rat intestinal fatty acid-binding protein (I-FABP) complexed

35 he structure of Escherichia coli-derived rat intestinal fatty acid-binding protein (I-FABP) exhibits

36 iganded form of Escherichia coli-derived rat intestinal fatty acid-binding protein (I-FABP) has been

37 (apo) forms of Escherichia coli-derived rat intestinal fatty acid-binding protein (I-FABP) have been

38 ver fatty acid-binding protein (L-FABP), and intestinal fatty acid-binding protein (I-FABP) in order

39 ated on the day of the initial rise in serum intestinal fatty acid-binding protein (I-FABP) would res

40 acid-binding protein (A-FABP) and 17 of the intestinal fatty acid-binding protein (I-FABP), at locat

41 lysaccharide (LPS), endotoxin core antibody, intestinal fatty acid-binding protein (I-FABP), soluble

42 man genetic determinants of plasma levels of intestinal fatty acid-binding protein (I-FABP/FABP2), a

43 necrosis factor [TNF]), enterocyte turnover (intestinal fatty acid binding protein [I-FABP]), lipopol

44 Intestinal fatty acid binding protein (IFABP) appears to

45 ccur during the folding and unfolding of rat intestinal fatty acid binding protein (IFABP) are descri

46 The human intestinal fatty acid binding protein (IFABP) binds long

47 This problem has been simplified for intestinal fatty acid binding protein (IFABP) by incorpo

48 Rat intestinal fatty acid binding protein (IFABP) displays a

49 Intestinal fatty acid binding protein (IFABP) is a membe

50 The intestinal fatty acid binding protein (IFABP) is a small

51 The intestinal fatty acid binding protein (IFABP) is compose

52 The rat intestinal fatty acid binding protein (IFABP) primarily

53 Using the intestinal fatty acid binding protein (iFABP) promoter,

54 ta is a functional all-beta sheet variant of intestinal fatty acid binding protein (IFABP) that was g

55 S) measurements have been carried out on the intestinal fatty acid binding protein (IFABP) to study m

56 a pancreas-specific transcription factor and intestinal fatty acid binding protein (IFABP), a marker

57 orporation of 4-(19)F-phenylalanine into the intestinal fatty acid binding protein (IFABP), a protein

58 , including alpha-lactalbumin, cytochrome c, intestinal fatty acid binding protein (IFABP), and myogl

59 eins, ileal lipid binding protein (ILBP) and intestinal fatty acid binding protein (IFABP), were exam

60 regulator (pCFTR) cDNA under control of the intestinal fatty acid-binding protein (iFABP) promoter w

61 acrophage migration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proin

62 his study evaluated the usefulness of plasma intestinal fatty-acid binding protein (IFABP) levels in

63 location markers (LPS, soluble CD14 [sCD14], intestinal fatty acid-binding protein [iFABP], and endot

64 s of four beta-sheet proteins, namely IFABP (intestinal fatty acid-binding protein), ILBP (ileal fatt

65 tive was to identify factors associated with intestinal fatty acid-binding protein in critically ill

66 individuals had higher plasma levels of LPS, intestinal fatty acid binding protein (indicating entero

67 The intestinal fatty acid binding protein is composed of two

68 The intestinal fatty acid binding protein is one of a family

69 Intestinal fatty acid-binding protein is a marker of ent

70 troscopy, the bands contained both liver and intestinal fatty acid-binding proteins (L- and I-FABP) a

71 n of CYP1A1, CYP2D6, cytochrome b5, liver or intestinal fatty acid binding proteins, or villin.

72 e isomaltase, cdx-2 homeodomain protein, and intestinal fatty acid binding protein promoter regions.

73 nsgenic mice, generated by utilizing the rat intestinal fatty acid-binding protein promoter (Fabpi),

74 by labeling site-specific mutants of the rat intestinal fatty acid binding protein (rI-FABP) with acr

75 d, there was a marked delay in expression of intestinal fatty acid binding protein, suggesting a role

76 xpression, the genomic sequence encoding the intestinal fatty acid binding protein was used.

77 The GI mucosal intestinal fatty acid-binding protein was decreased afte

78 icator of FFA, ADIFAB (acrylodan-labeled rat intestinal fatty acid-binding protein), was microinjecte

79 A mutant of a beta-barrel protein, rat intestinal fatty acid binding protein, was predicted to

80 Blood citrulline and intestinal fatty acid binding protein were determined as

81 Site-specific variants of rat intestinal fatty acid-binding protein were constructed t

82 te directly activity of the promoter for the intestinal fatty acid-binding protein (xIFABP) gene, whi